切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (02) : 133 -137. doi: 10.3877/cma.j.issn.2095-3224.2016.02.05

所属专题: 文献

青年专家论坛

结直肠癌寡转移的放射治疗策略
任骅1, 金晶1,()   
  1. 1. 100021 北京,中国医学科学院 北京协和医学院肿瘤医院放疗科
  • 收稿日期:2016-02-17 出版日期:2016-04-25
  • 通信作者: 金晶
  • 基金资助:
    国家自然科学基金资助项目(81272510)

Strategy of radiotherapy for oligometastasis from colorectal cancer

Hua Ren1, Jing Jin1,()   

  1. 1. Department of Radiotherapy, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
  • Received:2016-02-17 Published:2016-04-25
  • Corresponding author: Jing Jin
  • About author:
    Corresponding author: Jin Jing, Email:
引用本文:

任骅, 金晶. 结直肠癌寡转移的放射治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2016, 05(02): 133-137.

Hua Ren, Jing Jin. Strategy of radiotherapy for oligometastasis from colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(02): 133-137.

结直肠癌寡转移是目前研究的重要领域之一。肝转移、肺转移及多部位寡转移的立体定性放射治疗研究逐步开展。直肠癌寡转移患者的盆腔放疗,国际上已经形成了推荐转移性直肠癌接受盆腔放疗的多学科共识。

Oligometastasis from colorectal cancer is one of the important fields of current research. Clinical trials of stereotactic body radiotherapy for liver, lung or multi-organ metastasis are gradually developed. There has been an international MDT consensus on recommendation of pelvic irradiation for patients with oligometastasis from rectal cancer.

表1 寡转移给予SBRT(5个分次)的正常组织限量表
[1]
Hellman S, Weichselbaum R. Oligometastases. J Clin Oncol, 1995, 13(1): 8-10.
[2]
Nordlinger B, Sorbye H, Glimelius B,et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.
[3]
Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol, 2012, 23(10): 2619-2626.
[4]
Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013, 24(Suppl 6): vi81-88.
[5]
Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol, 1995, 34(6): 861-870.
[6]
Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys, 2012, 82(3): 1047-1057.
[7]
Chang DT, Swaminath A, Kozak M, et al. Sterotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer, 2011, 117(17): 4060-4069.
[8]
Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol, 2011, 18(4): 1081-1087.
[9]
Robertson JM, Lawrence TS, Walker S, et al. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys, 1995, 32(2): 445-450.
[10]
Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol, 2000, 18(11): 2210-2218.
[11]
Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol, 2005, 23(34): 8739-8747.
[12]
Ohri N, Jackson A, Mendes Romeo A, et al. Local control following stereotactic body radiotherapy for liver tumor: a preliminary report of the AAPM working group for SBRT. Int J Radiat Oncol Biol Phys, 2014, 50 (supplement): S52. ABSTRCT 106.
[13]
Liu E, Stenmark MH, Lee OE, et al. SBRT as an alternative to RFA for the treatment of primary and metastatic liver tumors. Journal of Clinical Oncology, 2012 Gastrointestinal Cancers Symposium. 2012, 30: No 4suppl (February 1 Supplement), ABSTRCT 158.
[14]
梁建伟,周志祥,刘骞,等.可切除结直肠癌肺转移的预后因素分析.中华肿瘤杂志,2010,32(9): 694-697.
[15]
Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol. 2007, 34(3): 186-196.
[16]
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 2015, 16(6):630-637.
[17]
Salama JK, Kirkpatrick J, Yin FF. Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol, 2012, 9(11): 654-665.
[18]
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol, 2009, 27(10): 1572-1578.
[19]
Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1516-1522.
[20]
Gunjur A, Duong C, Ball D, et al. Surgical and ablative therapies for the management of adrenal ′oligometastases′ - A systematic review. Cancer Treat Rev. 2014, 40(7): 838-846.
[21]
Pastorino U, Buyse M, Friedel G, et al. The International Registry of Lung Metastases: Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg, 1997, 113(1): 37-49.
[22]
Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys, 2005, 62(5): 1371-1378.
[23]
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol, 2009, 27(10): 1572-1578.
[24]
Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): s94-s100.
[25]
Assumpcao L, Choti MA, Gleisner AL, et al. Patterns of recurrence following liver resection for colorectal metastases. Arch Surg, 2008, 143(8): 743-749.
[26]
Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118(21): 5414-5423.
[27]
Logan JK, Huber KE, Dipetrillo TA, et al. Patterns of care of radiation therapy in patients with stage IV rectal cancer: a Surveillance, Epidemiology, and End Results analysis of patients from 2004 to 2009. Cancer, 2014, 120(5): 731-737.
[28]
Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg, 2010, 97(7): 580-587.
[29]
Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, et al. Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol, 2013, 107(2): 171-177.
[30]
Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer, 2013, 13: 279.
[31]
Van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol, 2013, 24(7): 1762-1769.
[32]
Tyc-Szczepaniak D, Wyrwicz L, Kepka L, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol, 2013, 24(11): 2829-2834.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[4] 施烨鑫, 马翔, 鲁明, 夏青城, 王鹏超, 宋青雨, 赵庆洪. 腹腔镜下结直肠肿瘤定位研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 463-466.
[5] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[6] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[7] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[8] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[9] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[12] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[13] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[14] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[15] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?